Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665080 | SCV000789141 | likely pathogenic | beta Thalassemia | 2017-01-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000665080 | SCV000917507 | pathogenic | beta Thalassemia | 2022-11-02 | criteria provided, single submitter | clinical testing | Variant summary: HBB c.93-15T>G alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 2/4 computational tools predict this variant creates cryptic 3' acceptor site. At least one publication reports experimental evidence that this variant affects mRNA splicing. Transient expression studies revealed a 4-fold decrease in the amount of RNA produced with > 99% of it being abnormally spliced (example: Metherall_1986). The variant was absent in 251042 control chromosomes (gnomAD). c.93-15T>G has been reported in the literature in multiple compound heterozygote and homozygote individuals affected with Beta Thalassemia (example: Metherall_1986, Chouk_2004 and Jarjour_2014). These data indicate that the variant is very likely to be associated with disease. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Laboratory of Medical Genetics, |
RCV004568488 | SCV005051817 | pathogenic | Beta-thalassemia HBB/LCRB | 2024-02-01 | criteria provided, single submitter | curation | |
OMIM | RCV000016713 | SCV000036983 | pathogenic | Beta zero thalassemia | 1986-10-01 | no assertion criteria provided | literature only | |
The ITHANET community portal, |
RCV000665080 | SCV001244511 | pathogenic | beta Thalassemia | 2019-11-25 | no assertion criteria provided | curation | |
Natera, |
RCV000665080 | SCV002089237 | pathogenic | beta Thalassemia | 2017-03-17 | no assertion criteria provided | clinical testing |